In our study, the majority of breast cancer treatments, including chemotherapy, anti-HER2 therapy, AIs, and TMX, were identified as risk factors for osteoporosis in younger women diagnosed with breast cancer before the age of 50. The gene discussed is ERBB2; the disease is breast carcinoma.